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112 Poster Session IIsource: 119 PB/31 BM) were retrospectively analyzed. Their diag-
noses were 90 acute leukemia, 30 CML, 6 MDS and 24 other dis-
eases. Multiplex PCR method was performed to amplify 16 STR
loci (D3S1358, HUMvWA, D16S539, D2S1338, Amelogenin,
D8S1179, D21S11, D18S51, D19S433, THO1, FGA, D7S820,
CSF1PO, D13S317, TPOX, D5S818) (ABI Prism 3130). The loci
examined were classified as complete matched (CM), partially
matched (PM), and fully mismatched (FMM) between donors and
recipients.
Results: The loci of D13S317, D18S51 and D2S1338 were the
most informative, while the loci of TPOX and CSF1PO were the
least. The incidence of acute GvHD was 46.7% (n 5 69), which
acute severe GvHD (grII-IV) was observed in only 31 patients.
Chronic GvHD was developed in 63.4% patients. The incidence
of grII-IV GvHD was higher in patient with CM in TPOX loci
(p 5 0.02). Chronic GvHD was more frequent in the patients
with PM in D5S818 loci than those with CM or MM (p 5 0.016).
While PMD21S11 increasedTRM,MMor PM inD5S818 loci de-
creased the TRM. In our cohort analysis, 2-year probability of dis-
ease-free survival(DFS) and overall survival(OS) were 58.1 6 5.5%
and 67.56 4.4%, respectively. TheCM inD21D11 locus (p5 0.07)
and PM in D5S818 locus (p 5 0.009) prolonged the probability of
DFS. In multivariate analysis, these loci had an impact onDFS (p5
0.055 ve p5 0.005). D19S433 and D5S818 loci had an effect on the
OS. We repeated similar analyses into two groups, mismatched
(MM) group, which FMM and PM was accepted as a whole group
or CM group, while the incidence of grII-IV GvHD was higher
in patients with CM of D18S51 and TPOX loci, the chronic
GvHD was more frequent in those with CM D5S820 loci. Similar
as the first analyses MM in D21S11 and CM in D5S818 affected
both TRM and DFS. Besides, MM in FGA locus decreased TRM
and prolonged DFS. The impact of D5S818 on the OS also contin-
ued, additionallyD19S433 hadminimal effect on theOS. In conclu-
sion, some disparities of STR loci might affect the transplantation
outcome; however, these results should be analyzed together with
other co-variates and on multicenter basis.302
AN EVALUATION OF DNA METHYLATION CHANGES IN A PHASE I CLIN-
ICAL TRIAL OF LOW-DOSE 5-AZACITIDINE (AZA) GIVEN AS MAINTE-
NANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT)
Silva, L.1, Garcia-Manero, G.2, Giralt, S.1, McCormick, G.1,
Soriano, A.2, Champlin, R.1, Kantarjian, H.2, de Lima, M.1. 1 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX; 2 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX.
DNA methylation of CpG Islands is a frequently found epige-
netic alteration in AML andMDS that leads to deranged gene activ-
ity. Inhibition of the enzyme DNA methyltransferase is associated
with hypomethylation, and possibly, restoration of normal function
to genes critical for differentiation and proliferation. AZA is a DNA
hypomethylating agent that may induce increased tumor immuno-
genicity, potentially magnifying the GVL effect. Lower doses are
likely to be better tolerated after HSCT and to be effective inducers
of hypomethylation. We hypothesized that AZA after HSCT will
lower relapse rates, and designed a phase I clinical trial that also
uses a molecular surrogate endpoint for dose finding. Here we de-
scribe methylation changes in patients so treated.
Pts with AML or high-risk MDS not in first remission (CR) are
eligible. Three doses of AZA were studied: 8, 16, and 24 mg/m2
daily  5 starting on day 1 42. DNA was extracted from mononu-
clear cells of 22 pts that received AZA. The methylation status of
long interspersed nuclear elements (LINE) was analyzed by pyrose-
quencing as a surrogate marker of global DNA methylation before
and after AZA administration. Gene specific methylation changes
were studied using a methylated CpG island amplification(MCA)/
CpG array.
Median age was 57 years. Diagnoses were MDS (n 5 4) and
AML(n5 18). Disease status atHSCT:CR, 18% (n5 4), and active
disease, 82%(n 5 18). LINE methylation results were as follows:
baseline: 44.51%; on cycle 1, 5th day of AZA: 24 mg/m2 5
43.58%; 16 mg/m2: 36.93%; 8 mg/m2: 42.86%. Two pts have re-lapsed while on AZA.There has been nomajor drug-related toxicity
and no increase in GVHD incidence. Analysis of gene-specific
methylation is ongoing.
AZA in doses up to 24 mg/m2 can be safely administered early af-
ter HSCT. Given the lack of toxicity and low levels of changes in
DNA methylation observed, we are currently investigating higher
doses.303
ROLE OF EXTENSIVE SPLENOMEGALY IN PATIENTS WITH MYELOFI-
BROSIS UNDERGOING A REDUCED INTENSITY ALLOGENEIC STEM
CELL TRANSPLANT
Ciurea, S.O.1, Sadegi, B.1, Wilbur, A.1, Alagiozian-Angelova, V.1,
Gaitonde, S.1, Dobogai, L.1, Akard, L.P.2, Hoffman, R.3,4,
Rondelli, D.1,4. 1 University of Illinois at Chicago, Chicago, IL; 2 Indiana
Blood and Marrow Transplantation Program, Indianapolis, IN; 3 Mount
Sinai School of Medicine, New York, NY; 4 Myeloproliferative Disorder-
Research Consortium.
Allogeneic stem cell transplantation has been shown to restore
normal hematopoiesis in patients with intermediate or high risk pri-
mary myelofibrosis (PMF) or myelofibrosis preceeded by polycy-
themia vera or essential thrombocythemia. However, in patients
with PMF and extensive splenomegaly it is not clear whether trans-
plant is associated with an unacceptable risk or if splenectomy
should be performed prior to transplant. In this study, ten consec-
utive patients with myelofibrosis who were not splenectomized re-
ceived an allogeneic hematopoietic stem cell transplantation
(HSCT) from related or unrelated donors and were periodically
monitored by ultrasound or CT scan for 12 months after transplant
to assess the kinetics of the reduction of splenomegaly. These find-
ings were correlated with the time to resolution of marrow fibrosis,
time to engraftment and clinical outcome. Over a 12 month period
a progressive reduction in spleen size was observed in all the patients
and paralleled the reduction in marrow fibrosis. Of 10 patients, 5
with a splenic longitudinal diameter .30 cm showed a more pro-
longed time to engraftment ANC . 0.5  109/L (d 19 6 5 vs 13
6 2, p 5 0.05) and platelet . 20  109/L (d 75 6 104 vs 11 6 2,
p 5 0.06). However, of the 5 patients with more extensive spleno-
megaly only 2 experienced delayed engraftment of platelets (d 77
and 256, respectively). Full donor chimerism was observed in all pa-
tients within 60 days after transplantation regardless of the size of
the spleen. At a median follow-up of 51 months (range: 2–81) all
the patients are alive but 1 who died of a TTP like syndrome 2
months after transplant and had a small spleen at the time of trans-
plant. A clinical CR has been documented in 7 patients and 2 have
achieved clinical improvement according to to the criteria estab-
lished by the International Working Group for Myelofibrosis Re-
search and Treatment (IWG-MRT). These findings suggest that
allogeneic HSCT with RIC regimen can be safely performed in pa-
tients with extensive splenomegaly. Although in these patients the
time to achieve a full hematopoietic engraftment may be prolonged,
the significant risk of morbidity and mortality associated with sple-
nectomy may be avoided.304
EFFECT OF SUBSTITUTING FLUDARABINE AND THYMOGLOBULIN FOR
CYCLOPHOSPHAMIDE IN BUSULFAN-BASED CONDITIONING REGIMENS
ON T-CELL CHIMERISM AND OUTCOMES AFTER ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (HCT)
O’Donnell, P.V.1, Woolfrey, A.E.1, Storer, B.1, Sorror, M.L.1,
Furlong, T.1, Anasetti, C.2, Heimfeld, S.1, Flowers, M.1,
Appelbaum, F.R.1, Martin, P.J.1, Deeg, H.J.1. 1 Fred Hutchinson Cancer
Research Center, Seattle, WA; 2 H. Lee Moffitt Cancer Center, Tampa,
FL.
Substitution of cyclophosphamide by agents such as fludarabine
and thymoglobulin in busulfan-based conditioning regimens has
been used to reduce complications after allogeneic HCT. We per-
formed a retrospective analysis of outcomes among 348 patients
Poster Session II 113who had HCT since 2001 with the use of 5 myeloablative condi-
tioning regimens: BuCY 6 Thymoglobulin, FluBu, or FluBu 1
Thymoglobulin with different doses of Flu designated Flu[1(120
mg/m2)]BuThy and Flu[2(250 mg/m2)]BuThy. Grafts consisted
of unmanipulated bone marrow or growth factor-mobilized blood
cells from related or unrelated donors, except for 9 patients who re-
ceived BuCY and mobilized blood cells from related donors that
were 90% depleted of T-cells. Donor chimerism in recipient blood
T-cells (CD3) and granulocytes (CD331) was measured at day 80
after HCT.
Patient characteristics in the 5 groups were similar: median age
49, 91% MDS or AML (64% high-risk), 51% unrelated donors,
88% PBSC, 59% HCT-CI $1. Donor chimerism of granulocytes
was complete by day 180 in all groups, but persistent mixed
T-cell chimerism was observed in certain groups. Compared to pa-
tients who received BuCY with unmanipulated allografts, the inci-
dence of mixed chimerism with .50% recipient T-cells was
higher among patients who received Flu, bone marrow grafts or
T-cell depleted grafts (e.g., Flu[1]BuThy: OR 14.5, p\ 0.0001).
Most patients with mixed chimerism at day 80 had full donor
T-cell chimerism at 1 yr after HCT, but some patients with
malignancy in complete remission at 3 yr continue to have per-
sistent mixed T-cell chimerism.
Compared to BuCY controls, improved outcomes with reduced
regimen-related toxicity were observed in the 22 patients who re-
ceived Flu[1]BuThy. After adjustment for age, disease risk, donor
type,HCT-CI and prior CMV infection in the recipient, the Flu[1]-
BuThy group had significantly lower rates of acute GvHD (HR
0.50, p 5 0.02), chronic GvHD (HR 0.31, p 5 0.003) and NRM
(HR 0.25, p 5 0.05), although relapse was not significantly in-
creased (HR 1.13, p 5 0.87) and overall survival was not signifi-
cantly improved (HR 5 0.60, p 5 0.19). In contrast, NRM and
survival in the Flu[2]BuThy and BuCY groups showed no statisti-
cally significant differences. In general, addition of thymoglobulin
for GvHD prophylaxis significantly reduced the incidence of
chronic GvHD. A prospective, randomized trial is needed to deter-
mine whether superior outcomes can be achieved after conditioning
with Flu[1]BuThy as compared with BuCy.305
THYMOGLOBULIN RABBIT ANTI-THYMOCYTE GLOBULINS (r-ATG)
INDUCES FASTER PLATELET RECOVERY AND DOES NOT SUPPRESS
GRANULOCYTE ENGRAFTMENT IN A NON-MYELOABLATIVE STEM
CELL TRANSPLANTATION SETTING
Shapira, M.Y., Resnick, I.B., Gesundeheidt, B., Bitan, M.,
Ackerstein, A., Samuel, S., Drey, L., Verkholevsky, Y., Slavin, S.,
Or, R. Hadassah – Hebrew University Medical Center, Jerusalem, Israel.
Introduction: : The role of anti thymocyte globulin in GVHD
prevention is well established, but it is also known that anti thymo-
cyte globulin induces leucopenia and thrombocytopenia and as such
might theoretically delay engraftment. Additionally, fast platelet
engraftment is a marker for good hematopoietic stem cell graft
function.We have prospectively compared the effect of Thymoglo-
bulin on engraftment of granulocytes and platelets following a single
non-myeloablative conditioning protocol in a randomized study.
Methods: 28 consecutive patients undergoing SCT were condi-
tioned with the NST protocol (I.V. fludarabine 30 mg/m2/day
(days -10 to -5) and I.V. busulfex (3.2 mg/kg on days 6 and 5),
with or without I.V. Thymoglobulin according to randomization
(days 4 to 1). Thymoglobulin dosing schedule: a cumulative dose
of 7.5 mg/kg r-ATG was given with the following program 0.5
mg/kg day -4, 2.0 mg/kg day -3, 2.5 mg/kg day -2, 2.5 mg/kg day
-1. Patients were followed for engraftment of leukocytes and plate-
lets. Results: only one patient rejected the graft (conditioned with-
out Thymoglobulin, NS). In 4 patients underlying disease
progression prevented engraftment of either ANC or platelets (2
per group). The median time to ANC engraftment was similar be-
tween the groups, 156 2.8 and 146 2.9 days for the Thymoglobu-
lin and control groups respectively (p5 0.21). However, themedian
time for platelet engraftment was significantly shorter in patients re-
ceiving Thymoglobulin as part of the conditioning. Platelet recov-
ery occurred 9.5 6 1.2 and 11 6 2.5 days for the Thymoglobulinand control groups respectively (p 5 0.018). Conclusions: In the
non-myeloablative setting, Thymoglobulin induces faster platelet
recovery and does not delay ANC engraftment.306
A COMPARISON OF MEASURED VS. CALCULATED CREATININE CLEAR-
ANCE AND THEIR LACK OF ASSOCIATION WITH RENAL REGIMEN RE-
LATED TOXICITY AFTER AUTOLOGOUS AND ALLOGENEIC BMT
Hahn, T., Dunford, L., Butler, B., Stento, N., Smiley, S., Battiwalla, M.,
McCarthy, P.L. Roswell Park Cancer Institute, Buffalo, NY.
Standard BMT eligibility criteria generally include glomerular
filtration rate (GFR) $50 ml/min for myeloablative and GFR
$40 ml/min for nonmyeloablative regimens. The most accurate,
but costly, method ofGFRmeasurement is urinary clearance ofmo-
lecular isotopes such as 99m Tc-DTPA. In BMT pts, GFR is com-
monly estimated by creatinine clearance in a 24 hour urine
collection (24 hr CrCl), a time-consuming and error-pronemethod.
4 equations incorporate different clinical variables to estimate CrCl:
Cockroft-Gault (CG), modified CG (mCG), Modification of Diet
in Renal Disease 1 (MDRD1) and MDRD2. The study objectives
were to determine which of 4 calculations consistently underesti-
mates measured CrCl pre-BMT and to determine if any were
correlated with renal regimen related toxicity (RRT). We retro-
spectively analyzed 100 consecutive allo (n 5 50) or auto (n 5 50)
BMT pts from 1/06 to 4/07 to compare measured CrCl with each
of the 4 formulas using linear regression and Wilcoxon signed
rank test. Renal RRT was defined using the Bearman scale: no in-
crease from baseline serum Cr (gr 0), any increase over baseline
(gr 1), doubling of baseline (gr 2), dialysis (gr 3), or death from renal
RRT (gr 4), with an incidence of 24%, 57%, 18%, 1% and 0%, re-
spectively. All 4 formulas were significantly (p\ .001) correlated to
measured CrCl with correlation coefficients (R) 5 .63 (CG), .61
(mCG), .50 (MDRD1) and .54 (MDRD2). When stratified by
gender, CG had the highest R for women (R 5 .679, p\ .001),
while MDRD1 had the highest for men (R 5 .40, p 5 .003).
MDRD1 consistently underestimated CrCl in the highest propor-
tion of pts (65%, p \ .001), compared to MDRD2 (65%, p 5
.001), mCG (54%, p5NS) and CG (33%, p 5 .001). Measured
CrCl, serum Cr, and all 4 calculations were not predictive of renal
RRT post-BMT. Significant univariate predictors of gr 2–3 renal
RRT were: alloBMT, reduced intensity/nonmyeloablative regi-
mens (RICNMA), KPS#80 and albumin#3.7 g/dL. In alloBMT,
BMI .35, KPS #80 and albumin #3.8 g/dL were significantly as-
sociated with gr 2–3 renal RRT, however in autoBMT baseline se-
rum Cr$1.1 was the only significant factor. Any of the 4 equations
can replace the 24 hr CrCl. CG is closest to, but overestimates CrCl
in 67% of pts. In comparison,MDRD1 consistently underestimates
CrCl in 65%. Larger analyses may better define subgroups at risk
for renal RRT. Our results suggest a lower CrCl threshold may
be acceptable for BMT due to the relatively low gr 2–4 renal
RRT incidence observed.307
MYELOABLATIVE ALLOGENEIC STEM CELL TRANSPLANTATION IN 424
PATIENTS USING BUSULFAN AND CYCLOPHOSPHAMIDE
Floisand, Y.1, Tjonnfjord, G.E.1, Gedde-Dahl d.y., T.1, Heldal, D.1,
Egeland, T.2, Dybedal, I.1, Holme, P.A.1, Brinch, L.C.1. 1 Rikshospitalet
University Hospital, Oslo, Norway; 2 Rikshospitalet University Hospital,
Oslo, Norway.
Background/Aims: From 1985 to 2007, 424 adult patients re-
ceived Busulfan Cyclophosphamide (Bu4Cy2) as conditioning regi-
men before allogeneic stem cell transplantation in our institution.
In this study we analyzed this group with regard to overall survival,
LFS, TRM and the incidence of complications.
Patient Material/Methods: 424 patients underwent ASCT;
43% female (N 5 185) and 57% male(N 5 239). Median age was
39.9 y (15.4–60.7). 263 patients (62%) received transplants from
family donors and 161 (38%) from matched unrelated donors
